Screening for Duchenne muscular dystrophy
Duchenne muscular dystrophy can be diagnosed with confidence before it is clinically apparent, and excluded with certainty where it may have seemed clinically obvious. This has been made possible by the demonstration of a grossly raised level of serum creatine phosphokinase (CPK) (Ebashi et al., 1959; Dreyfus, Schapira, and Demos, 1960) . Highest levels (up to 100 times normal) are found early in the disease and tend to decline with age and progressive loss of muscle bulk, though remaining raised. A peak is probably reached at about 1-2 years, but high levels are already present soon after birth. Heyck, Laudahn, and Carsten (1966) recorded a high level of CPK (and other enzymes) in an infant 9 days of age from a family at risk, but no one has yet documented a raised enzyme level in the cord blood of a proven case of Duchenne dystrophy. Diagnosis can be further confirmed, even in the preclinical stage, by electromyography and muscle biopsy. A grossly raised CPK by itself is no index of severity or prognosis, since equally high levels can occur in the milder X-linked Becker type of dystrophy.
In families at risk for Duchenne dystrophy early diagnosis can thus be made or excluded in male infants. Zellweger and Antonik (1975) In spite of the relatively high estimated incidence of about 1 in 3000 to 4000 male births (Zellweger and Antonik, 1975) and the potential value of genetic counselling in preventing a recurrence in the family, it is doubtful whether there would be any enthusiasm for large-scale screening of newborns for Duchenne dystrophy at the present time. However, should the circumstances change and the possibility of treatment became available, then this would be a very worthwhile undertaking. Under such circumstances the method would have to be practical, economical, and of proven reliability and consistency in general laboratory use. Zellweger and Antonik claim that with their method at least 5 assays can be obtained from a single drop of blood, 600 assays can be performed in a day by one technician, and samples can be stored at room temperature up to 6 weeks.
Beckmann and his colleagues in West Germany (Beckmann et al., 1974 a, b) have compared this new method with the standard CPK technique and found it to be reliable. They have favoured the introduction of a screening programme and in their initial survey (R. Beckmann and G. Scheuerbrandt, personal communication, 1976 ) of 16 520 newborn infants (from 120 hospitals in South West Germany) have detected 5 boys with preclinical muscular dystrophy which would give an incidence of 1 in 1700 male births (assuming 52% of births in Germany are male). This would suggest a higher incidence than any previous estimates, which have ranged from 1 in 3000 male births to 1 in 8000. In addition, Beckmann subsequently also identified 5 female carriers in the families of these 5 males. If a screening programme is introduced, it may well be worth screening all infants, both male and female, since potential female carriers of Duchenne dystrophy may well have higher CPK levels early on which may gradually decline with age (as happens in affected boys) and possibly drop to within normal levels by the time they reach adult life, thus accounting for some of the 30% or so of known carrier females who have normal CPK levels.
In a poll of parents, Beckmann and Scheuerbrandt (personal communication, 1976) found that 87% of those with an affected son said they would wish to know that their newborn son had Duchenne muscular dystrophy, as did 86% of parents of healthy schoolchildren.
In order to minimize the risk of false-positives and particularly false-negatives, the range of normal infants would have to be carefully assessed and the influence of perinatal factors on the levels taken into account.
In this issue Gilboa and Swanson (1976) once again highlight the wide range of CPK in normal newborns. In some the level was up to 10 times the normal. Like previous authors they have also noted the lower level in cord blood than in capillary blood and a peak level in the infant during the first 24 hours after delivery. The mean capillary level was 14 6% lower than that of simultaneous venous samples but did not reach statistical significance. In contrast to the experience of previous authors they did not find the same consistent correlations between birth trauma, mode of delivery, and CPK levels. They wisely suggest that any screening for muscular dystrophy should be postponed beyond the immediate newborn period. 
